Soligenix Inc diskutieren
Soligenix Inc.
WKN: A3D506 / Symbol: SNGX / Name: Soligenix / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
Quitte stimmt dem Sentiment von 'Buy' zu
= Soligenix ( SNGX ) early Monday said it has received notices of allowance from regulators for its patent applications in Europe and Canada extending protections for its proprietary ThermoVax vaccine heat stabilization platform technology. The main claims in these new patents cover formulations of the biotech company's RiVax thermostabilized ricin toxin vaccine.
SecteurRecherche biotechnologique et médicale Agenda 27/09 | 15:00 Assemblée générale
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease.
It operates through the BioTherapeutics, and Vaccines/BioDefense segments.
The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma.
The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate.
The company was founded in 1987 and is headquartered Princeton, NJ.
Nombre d'employés : 18 personnes.
piccolo90 stimmt dem Crowdsentiment von 'Buy' zu
piccolo90 stimmt am 02.09.2018 dem Buy-Crowdsentiment mit dem Kursziel 2.5$ zu.
SecteurRecherche biotechnologique et médicale Agenda 14/11 Publication de résultats
Soligenix, Inc. s’engage dans le développement et la commercialisation de maladies rares.
Il opère à travers les segments BioTherapeutics et Vaccines / BioDefense.
Le segment BioTherapeutics propose une thérapie photodynamique (SGX301) utilisant de l’hypericine synthétique topique activée par une lumière fluorescente visible sans danger pour le traitement du lymphome cutané à lymphocytes T.
Le segment Vaccines / BioDefense comprend les programmes de développement actif de RiVax, candidat vaccin à la toxine de la ricine, OrbeShield, candidat thérapeutique du syndrome de radiation aiguë, et SGX943, candidat thérapeutique à la mélioïdose.
La société a été fondée en 1987 et est basée à Princeton, NJ.
Nombre d'employés : 18 personnes.
Entzündung der Mundschleimhaut als Nebenwirkung der Krebstherapie
Soligenix up 16% premarket on advancement of late-stage study of SGX942
Thinly traded nano cap Soligenix (NASDAQ:SNGX) is up 16% premarket on light volume in response to its announcement that enrollment in its Phase 3 clinical trial, DOM-INNATE, evaluating SGX942 for the treatment of oral mucositis (OM) in head and neck cancer patients has reached ~90 subjects, enough to support the planned interim analysis by the independent Data Monitoring Committee.
The primary endpoint is the duration of severe OM over ~13-week period compared to placebo.
Recruitment should be completed this year with topline results expected in H1 2020, pending the outcome of the interim analysis.
Secteur Recherche biotechnologique et médicale Agenda 08/08 Publication de résultats
Nombre d'employés
: 18 personnes.
Neueste Beiträge
RudolfL in Bilfinger SE diskutieren